F
Fabrice Barlesi
Researcher at Aix-Marseille University
Publications - 666
Citations - 36214
Fabrice Barlesi is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 64, co-authored 582 publications receiving 25403 citations. Previous affiliations of Fabrice Barlesi include Institut Gustave Roussy & Nord University.
Papers
More filters
Journal ArticleDOI
Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC
M. Lind,Scott N. Gettinger,Hossein Borghaei,Julie R. Brahmer,Laura Q.M. Chow,Marco Angelo Burgio,J. De Castro Carpeno,Adam Pluzanski,Oscar Arrieta,O. Aren Frontera,Rita Chiari,Charles Butts,Joanna Wojcik-Tomaszewska,Bruno Coudert,M.C. Garassino,Neal Ready,E. Felip,M. Alonso Garcia,David M. Waterhouse,Manuel Domine,Fabrice Barlesi,S.J. Antonia,M. Wohlleber,David E. Gerber,Grzegorz Czyzewicz,David R. Spigel,L. Crinò,W. Eberhardt,Anthony Li,S. Marimuthu,Everett E. Vokes +30 more
Journal ArticleDOI
1302PDIFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP)
Nicolas Girard,C. Audigier Valette,Jacques Cadranel,Isabelle Monnet,J. Hureaux,W. Hilgers,E. Fauchon,Elizabeth Fabre,Benjamin Besse,P. Brun,D. Coëtmeur,E. Quoix,Pierre Mourlanette,Fabrice Barlesi,S. Bordenave-Caffre,T. Egenod,P. Missy,Franck Morin,D. Moro-Sibilot,Olivier Molinier +19 more
TL;DR: Real-life experience with nivolumab in patients with advanced Non-Small Cell Lung Cancer (NSCLC) and efficacy and safety of nivlumab and post-nivolumsab treatment in the French Expanded Access Program (EAP) are studied.
Journal ArticleDOI
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Consuelo Buttigliero,Frances A. Shepherd,Fabrice Barlesi,Brian Schwartz,Sergey Orlov,Adolfo Favaretto,Armando Santoro,Vera Hirsh,Rodryg Ramlau,Adele R. Blackler,Joanna Roder,David R. Spigel,Silvia Novello,Wallace Akerley,Giorgio V. Scagliotti +14 more
TL;DR: VeriStrat showed a prognostic role within Eastern Cooperative Oncology Group (ECOG) performance score (PS) categories and regardless of treatment arm and EGFR status, suggesting that Veri Strat could be used to identify EGFR mutation-positive patients who will have a poor response to EGFR tyrosine kinase inhibitors.
Journal ArticleDOI
Should chemotherapy (Cx) for advanced non-small cell lung cancer (NSCLC) be platinum-based? A literature-based meta-analysis of randomized trials
TL;DR: Platinum-based Cx are world-wide accepted regimens in the treatment of advanced NSCLC and third generation anti-cancer agents share a better efficacy/toxicity profile when compared with conventional chemotherapy methods.
Journal ArticleDOI
Stratégies de prise en charge des métastases cérébrales des malades atteints de cancers bronchiques primitifs
Fabrice Barlesi,Natalia Khobta,Agnès Tallet,Anthony Gonçalves,David Azria,Jean-Philippe Spano,Antoine F. Carpentier,Jean Régis,Philippe Metellus +8 more
TL;DR: Brain metastases from primary lung cancer represent 40% of all brain metastases and management of these patients will depend on the circumstances of diagnosis, the cancer history, the histology and the number of lesions.